19:11 , May 31, 2019 |  BC Extra  |  Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
18:51 , Feb 22, 2019 |  BC Week In Review  |  Company News

Abbott and Novo Nordisk to deliver insulin dose data from pens to the cloud

Abbott Laboratories (NYSE:ABT) and Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) partnered under a non-exclusive deal to integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into digital health tools compatible with...
13:54 , Feb 14, 2019 |  BioCentury  |  Finance

HKEX: where East meets West

Unfazed by the shaky start of the Hong Kong stock exchange’s new biotech chapter, HKEX CEO Charles Li thinks its position at the nexus of East and West will underpin its long-term success. With more...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest PPARα agonists could enhance the efficacy of adoptive T cell therapies for melanoma. In a mouse model of melanoma, adoptive transfer of CD8 + T cells pretreated with a tool...
18:51 , Dec 14, 2018 |  BC Week In Review  |  Company News

FDA scraps proposal to let generic makers update labeling sans review

FDA scrapped a proposal to let generic makers independently update safety data on labels due to concerns of inconsistency and negative market impact, according to a Dec. 13 statement by FDA Commissioner Scott Gottlieb and...
23:15 , Oct 26, 2018 |  BioCentury  |  Product Development

R&D merry-go-round

An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition...
23:48 , Oct 15, 2018 |  BC Extra  |  Company News

Management tracks: Rhythm, Redpin

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) hired Murray Stewart as CMO of the metabolic disorder company. Stewart was CMO of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) until 2017 when he became head of R&D at Novelion Therapeutics Inc. (NASDAQ:NVLN)....
17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies identified a GSDMD inhibitor that could help treat sepsis. In vitro , the previously identified necroptosis inhibitor necrosulfamide bound GSDMD with a K d of 32 μM. In...
18:36 , Aug 23, 2018 |  BC Innovations  |  Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of...
17:16 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris. The candidate is a topical photoparticle therapy targeting the sebaceous...